Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Lonapegsomatropin (Skytrofa) vs MK-677 (Ibutamoren)
An educational, source-based comparison of Lonapegsomatropin (Skytrofa) and MK-677 (Ibutamoren) — how each peptide works, what it's researched for, and what to know before going deeper.
Prodrug of somatropin with a transient PEG linker that releases unmodified GH over ~1 week, providing once-weekly dosing for pediatric GH deficiency.
- Pediatric growth hormone deficiency
- • FDA-approved.
- • Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Orally bioavailable non-peptide ghrelin mimetic.
Technically a small-molecule ghrelin receptor agonist (not a peptide), often grouped with peptide GH research. Orally bioavailable, it elevates GH and IGF-1 over 24 hours and increases appetite.
- GH/IGF-1 elevation in adults
- Lean mass and bone density in elderly
- Sleep quality (slow-wave sleep)
- • Not FDA-approved.
- • Insulin resistance and fluid retention reported.
- • Banned by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Lonapegsomatropin (Skytrofa) | heiGHt trial | JCEM | 2021 | Non-inferior annualized height velocity vs daily somatropin. |
| MK-677 (Ibutamoren) | MK-677 increases GH and IGF-1 in elderly adults | Annals of Internal Medicine | 2008 | Two-year RCT showing sustained IGF-1 elevation and lean mass increase. |
Side-effect & safety grid
- FDA-approved.
- Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
- Not FDA-approved.
- Insulin resistance and fluid retention reported.
- Banned by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Lonapegsomatropin (Skytrofa) vs MK-677 (Ibutamoren) — Key differences
- Class: Lonapegsomatropin (Skytrofa) is classified as GH Analog · Endocrine, while MK-677 (Ibutamoren) is Growth Hormone Axis · Small Molecule.
- Primary research focus: Lonapegsomatropin (Skytrofa) — pediatric growth hormone deficiency; MK-677 (Ibutamoren) — gh/igf-1 elevation in adults.
- Tag: FDA-Approved · Endocrine vs Growth hormone · Oral.